Computed tomography-bronchoscopic simulation for guiding transbronchial fine needle aspiration of extramural targets: a phantom study.

OBJECTIVES: Extramural paratracheal/-bronchial tumors of the mediastinum and the hilum that cannot be seen in bronchoscopy constitute a particular challenge for transbronchial fine needle aspiration cytology. A software prototype was developed as a guidance tool to visualize extramural targets on computed tomography (CT)-bronchoscopy. A phantom study was conducted to evaluate this guidance tool. MATERIAL AND METHODS: For CT-bronchoscopic simulation extramural targets are visualized behind the semitransparent wall in the endoluminal view. An airway phantom with 16 targets was examined by 3 bronchoscopists. In a first pass the targets were bronchoscopically punctured in the conventional way only with knowledge of axial CT-sections. In a second pass guidance by CT-bronchoscopic simulation was used. A postinterventional CT scan of the phantom was conducted to analyze the spatial relationship between the marked puncture sites and the targets. The punctures were classified in hits and failed punctures due to deviation in distance and angle. RESULTS: The total hit rate of the 3 operators was significantly higher with CT-bronchoscopic simulation (32 of 48) than with the conventional method (14 of 48; P < 0.01). Concerning the failed punctures the deviation in distance and angle was significantly smaller with CT-bronchoscopic simulation (P < 0.01, P < 0.05, respectively). CONCLUSION: CT-bronchoscopic simulation significantly increased hit rate of bronchoscopic punctures of extramural lesions compared with conventional orientation using axial CT-sections in this phantom study. These results suggest that CT-bronchoscopic simulation might be a valuable tool for increasing yield and accuracy of bronchoscopic transbronchial fine needle aspiration in patients with mediastinal and hilar masses that are invisible for conventional bronchoscopy.

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.

PURPOSE: The efficacy and toxicity of bendamustine chemotherapy in relapsed small cell lung cancer (SCLC) was determined in this phase II trial. PATIENTS AND METHODS: Patients with cytologically or histologically proven SCLC, who had a sensitive relapse, which was defined as a relapse>or=2 months after completion of primary therapy, were eligible for this study. After informed consent patients received 120 mg/m2 of bendamustine on Days 1 and 2 every 3 weeks. A maximum of six cycles was administered. Primary endpoint was response rate, secondary endpoints included toxicity, progression free survival and overall survival (OS). RESULTS: Twenty-one patients with a median age of 59 years (range 47-76) were accrued to this trial. Six (29%) of 21 patients achieved a confirmed partial remission, 6 (29%) had stable disease and 9 (42%) patients progressed according to RECIST criteria. Median progression free survival was 4 months (95% CI 0-8, 3), median overall survival was 7 months (95% CI 5, 8-8, 2). One- and 2-year survival was 16% and 8%, respectively. Grade III/IV neutropenia occurred in 3 (15%) of 21 patients, 1 patient had a lethal Gram-negative sepsis in neutropenia. Two additional patients had pneumonia in the absence of neutropenia. Two patients (10%) had a grade III anemia, no grade III or IV thrombocytopenia was observed. CONCLUSION: This trial demonstrates efficacy of bendamustine in relapsed SCLC and a favourable toxicity profile. Therefore, single-agent bendamustine is a treatment option for patients with SCLC, who have responded to initial platinum containing chemotherapy and should further be investigated in randomized trials.